Prostate cancer (clinical) NBPDS



© Australian Institute of Health and Welfare 2024

This product, excluding the AlHW logo, Commonwealth Coat of Arms and any material owned by a third party or protected by a trademark, has been released under a Creative Commons BY 4.0 (CC BY 4.0) licence. Excluded material owned by third parties may include, for example, design and layout, images obtained under licence from third parties and signatures. We have made all reasonable efforts to identify and label material owned by third parties.

You may distribute, remix and build on this website's material but must attribute the AlHW as the copyright holder, in line with our attribution policy. The full terms and conditions of this licence are available at https://creativecommons.org/licenses/by/4.0/.

Enquiries relating to copyright should be addressed to info@aihw.gov.au.

Enquiries or comments on the METEOR metadata or download should be directed to the METEOR team at meteor@aihw.gov.au.

Prostate cancer (clinical) NBPDS

Identifying and definitional attributes

Metadata item type: Data Set Specification

METEOR identifier: 481386

Registration status: Health!, Standard 14/05/2015

DSS type: Data Set Specification (DSS)

Scope: The purpose of the Prostate cancer (clinical) National best practice data set

(PCNBPDS) is to define data standards for the national collection of prostate cancer clinical data so that data collected is consistent and reliable. Collection of this data set is not mandated but it is recommended as best practice where clinical cancer data are collected. It will facilitate more consistent data collection while enabling individual treatment centres or health service areas to develop data extraction and collection processes and policies that are appropriate for their

service settings.

The PCNBPDS is used in conjunction with the Cancer (clinical) National best practice data set (CCNBPDS). Mandatory reporting regulations have enabled population-based cancer registries in Australia to collect standard information on all incident cases of cancer apart from non-melanoma skin cancers, from which incidence, mortality and overall survival have been determined and trends monitored. The CCNBPDS provides a framework for the collection of more detailed and comprehensive clinical data such as stage of cancer at diagnosis, other prognostic characteristics, cancer treatment and patient outcomes.

The PCNBPDS will support prospective data collection from the time a person with cancer symptoms is referred or first presents to a hospital or specialist through the entire duration of their illness.

The definitions used in this data set are designed to capture the provision of cancer care on a day-to-day level. They relate to the cancer care pathway and the need to optimise care by correctly diagnosing, evaluating and managing patients with cancer. In addition, end-points and patterns of care can be monitored to understand both the appropriateness and effectiveness of cancer care.

The data elements specified provide a framework for:

- · promoting the delivery of evidence-based care to patients with cancer
- facilitating the ongoing improvement in the quality and safety of cancer management in treatment settings
- improving the epidemiological and public health understanding of cancer informing treatment guidelines; and
- professional education guiding resource planning and the evaluation of cancer control activities.

They will facilitate the aggregation of data across different treatment centres.

The underlying long-term goal is to provide data support to improve outcomes for patients by increasing the quality and length of life. For example, a comparison of the actual management of patients with best practice guidelines may identify shortfalls in treatment and limitations in access to treatment modalities for some patients.

Collection and usage attributes

Guide for use:

This data set is primarily directed at the clinical and clinical epidemiological use of cancer data. Treatment centres such as hospitals, radiotherapy centres and cancer specialist practices are the settings in which implementation of the Prostate cancer (clinical) NBPDS should be considered. The data set can also be used by a wider range of health and health-related establishments that create, use, or maintain records on health-care clients.

Comments: Glossary items

Glossary terms that are relevant to this data set are included here.

Androgen deprivation therapy

Brachytherapy

Clinical trial

Core biopsy

Erectile dysfunction

Extraprostatic extension

Faecal incontinence

Gleason score

Medical imaging

Prostate-specific antigen

Radiotherapy

Sexual Health Inventory for Men

Surgical procedure

Urinary incontinence

Urine voiding problems

Source and reference attributes

Submitting organisation: Cancer Australia

Relational attributes

Related metadata references:

See also <u>Cancer (clinical) NBPDS</u> <u>Health!</u>, Standard 14/05/2015

Metadata items in this Data Set Specification

Seq Metadata item Obligation Max No. occurs

1 Person—erectile dysfunction extent, SHIM score NN Mandatory 99

DSS specific information:

Collect this item at diagnosis of a person with prostate cancer (prior to the initiation of treatment).

2 <u>Person—erectile dysfunction assessment date, DDMMYYYY</u> Mandatory 99

3 Person—faecal incontinence indicator, yes/no/unknown code N Mandatory 99

DSS specific information:

Collect this item at diagnosis of a person with prostate cancer (prior to the initiation of treatment).

Seq No.	Metadata item	Obligation	Max occurs
4	Person—urinary incontinence indicator, yes/no/unknown code N	Mandatory	99
	DSS specific information:		
	Collect this item at diagnosis of a person with prostate cancer (prior to the initiation of treatment).		
5	Person—urinary incontinence pad use indicator, yes/no/unknown code N	Mandatory	99
	DSS specific information:		
	Collect this item at diagnosis of a person with prostate cancer (prior to the initiation of treatment).		
6	Person—urine voiding problem, symptom severity code N	Mandatory	99
	DSS specific information:		
	Collect this item at the point of diagnosis of a man with prostate cancer (prior to the initiation of treatment).		
7	Person—prostate-specific antigen level, nanograms per millilitre	Mandatory	99
	DSS specific information:		
	It is recommended that this item should be recorded at:		
	 diagnosis pre-treatment post treatment all subsequent follow-ups 		
8	Person—prostate-specific antigen test date, DDMMYYYY	Mandatory	99
	DSS specific information:		
	Collect in conjunction with Person—Prostate-Specific Antigen Test level, nanograms per millilitre.		
9	Person—prostate cancer diagnostic imaging, code NN	Mandatory	19
10	Person—prostate cancer diagnostic imaging, text X[X(99)]	Conditional	9
	Conditional obligation:		
	Collect this item when <u>Person—diagnostic imaging</u> , <u>prostate cancer diagnostic imaging code NN</u> equals other.		
11	Person with cancer—diagnostic histology indicator, yes/no/unknown code N	Mandatory	1
12	Person with prostate cancer—tissue collection method, code N	Conditional	9
	Conditional obligation:		
	Collect this item if <u>Person with cancer-diagnostic histology, yes/no/unknown code N</u> equals yes.		

Seq Metadata item **Obligation Max** No. occurs 13 Person with cancer—biopsy core, number N[NN] Conditional 9 Conditional obligation: Collect this item if Person with cancer—diagnostic histology indicator, yes/no/unknown code N equals yes. 14 Person with cancer—positive biopsy core, number N[NN] Conditional 9 Conditional obligation: Collect this item if Person with cancer-diagnostic histology, yes/no/unknown code N equals yes. 15 Person with cancer—core biopsy length, total millimetres NN.N Optional 19 16 Person with cancer—core biopsy tumour extent, percentage N[NNN] Optional 19 17 Person with cancer—core biopsy tumour length, total millimetres NN.N Optional 19 18 Person with cancer—histopathological grade, Gleason score code N[N] Mandatory 19 19 Person with cancer—histopathological grade, primary Gleason grade code N Mandatory 19 20 Person with cancer—histopathological grade, secondary Gleason grade code N Mandatory 19 21 Person with cancer—histopathological grade, tertiary Gleason Grade code N Mandatory 19 22 Person with cancer—lymphovascular invasion type, code N Mandatory 9 DSS specific information: Collect this item both after diagnostic testing/imaging is completed and after surgery. 23 Person with cancer—perineural invasion indicator, yes/no/not applicable/not Mandatory 9 stated/inadequately described code N DSS specific information: Collect this item both after diagnostic testing/imaging is completed and after surgery. 24 Person with cancer—extraprostatic extension focality, code N Conditional 9 Conditional obligation: Collect this item if Person with cancer—extraprostatic extension, yes/no/unknown/not stated/inadequately described code N equals yes and has been collected as part of the surgical removal of cancer. Do not collect this item if this relates to diagnostic assessment. 25 Person with cancer—extraprostatic extension indicator, present/indeterminate/not Mandatory 1 identified code N 26 Person with cancer—extraprostatic extension location, code N[N] Conditional 9 Conditional obligation: Collect this item if Person with cancer—extraprostatic extension, yes/no/unknown/not stated/inadequately described code N equals yes based on surgical pathology.

Seq Metadata item **Obligation Max** No. occurs 27 Person with cancer—distant metastatic site(s) at diagnosis, code N[N] Mandatory Conditional obligation: Record when cancer has metastasised to other sites. 28 Person with cancer—distant metastatic site(s) at diagnosis, topography code (ICD-O- Conditional 19 3) ANN.N Conditional obligation: Collect this item when Person with cancer—distant metastatic site(s) at diagnosis, code N[N] equals other. 29 Person with cancer—clinical trial entry status, code N Mandatory 9 30 Person with cancer—clinical trial identifier, text X[X(399)] Conditional 9 Conditional obligation: Collect this item when Person with cancer—clinical trial entry status, code N equals 2. 31 Person with cancer—date clinical trial entered, DDMMYYYY Conditional 9 Conditional obligation: Collect this item when Person with cancer—clinical trial entry status, code N equals 2. 32 Person with cancer—date clinical trial completed, DDMMYYYY Conditional 9 Conditional obligation: Collect this item when Person with cancer—clinical trial entry status, code N equals 2. Conditional 9 33 Person with cancer—clinical trial experimental agent or intervention, text X[X(399)] Conditional obligation: Collect this item when Person with cancer—clinical trial entry status, code N equals 2. 34 Cancer treatment—surgical procedure for prostate cancer, code N Mandatory 9 35 Person with cancer—pelvic lymph node dissection indicator, yes/no/not Mandatory 1 stated/inadequately described code N 36 Person with cancer—pelvic lymph node dissection laterality, code A Mandatory 19 37 Person with cancer—tumour focality indicator, code N Mandatory 9 DSS specific information: Record this item in relation to surgical pathology only. 38 Cancer treatment—surgical margin status, positive/negative/unknown code N Mandatory 9

Seq No.	Metadata item	Obligation	Max occurs
39	Cancer treatment—external beam radiotherapy type, code N[N]	Conditional	9
	Conditional obligation:		
	Collect if the patient has undergone external beam radiotherapy.		
40	Cancer treatment—brachytherapy indicator, yes/no code N	Mandatory	1
41	Cancer treatment—brachytherapy dose rate, code N	Conditional	9
	Conditional obligation:		
	Collect if Cancer treatment—brachytherapy, yes/no code N equals yes.		
42	Cancer treatment—androgen deprivation therapy indicator, yes/no/not applicable code N	Mandatory	1
43	Cancer treatment—androgen deprivation therapy purpose, code N	Conditional	9
	Conditional obligation:		
	Collect this item when <u>Cancer treatment—androgen deprivation therapy</u> , <u>yes/no/not applicable code N</u> equals yes.		
44	Cancer treatment—specialist support services type, code N[N]	Mandatory	29
45	Cancer treatment—specialist support services type, text X[X(99)]	Conditional	29
	Conditional obligation:		
	Collect this item when <u>Cancer treatment—specialist support services type, code</u> <u>N[N]</u> equals other.		
46	Cancer treatment—specialist support services date, DDMMYYYY	Conditional	29
	Conditional obligation:		
	Collect this item when <u>Cancer treatment—specialist support services indicator</u> , <u>yes/no/unknown code N</u> equals yes.		
47	Person with cancer—castrate resistance indicator, yes/no code N	Mandatory	1
48	Person with cancer—castrate resistance date, DDMMYYYY	Conditional	9
	Conditional obligation:		
	Collect this item when <u>Person with cancer—castrate resistance</u> , <u>yes/no code N</u> equals yes.		